The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study
Open accessAbstract
Background: The gender–age–physiology (GAP) model was developed to predict the risk of death. Comorbidities are common in idiopathic pulmonary fibrosis (IPF) and may impact on survival. We evaluated the ability of comorbidities to improve prediction of survival in IPF patients beyond the variables included in the GAP model. Methods: We developed a prediction model named TORVAN using data from two independent cohorts. Continuous and point-score prediction models were developed with estimation of full and sparse versions of both. Model discrimination was assessed using the C-index and calibrated by comparing predicted and observed cumulative mortality at 1–5 years. Results: Discrimination was similar for the sparse continuous model in the derivation and validation cohorts (C-index 71.0 versus 70.0, respectively), and significantly improved the performance of the GAP model in the validation cohort (increase in C-index of 3.8, p=0.001). In contrast, the sparse point-score model did not perform as well in the validation cohort (C-index 72.5 in the derivation cohort versus 68.1 in the validation cohort), but still significantly improved upon the performance of the GAP model (C-index increased by 2.5, p=0.037). Conclusions: The inclusion of comorbidities in TORVAN models significantly improved the discriminative performance in prediction of risk of death compared to GAP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Different composite predictors of outcome have been developed in the past years; however, clinical uptake and external validation is limited.(226–232)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [226]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citation2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Self-citationA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Self-citationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Cottin, V., Nunes, H., Brillet, P.-Y., Delaval, P., Devouassoux, G., Tillie-Leblond, I., Israel-Biet, D., Court-Fortune, I., Valeyre, D., & Cordier, J.-F. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00021005 · Cited by 1,004
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879
Cited by
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Self-citationThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Self-citationProgression of fibrosing interstitial lung disease
Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 185
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Metadata
- Authors
- Torrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C.
- Affiliations
- University of Catania (IT)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Erasmus MC (NL)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2018-12-21
- Volume
- 53
- Issue
- 3
- Pages
- 1801587
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2905932807
- Cited by
- 79
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 11 · 2022: 12 · 2021: 13 · 2020: 8 · 2019: 7
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, comorbidities, survival prediction, mortality risk, gap model, prediction model discrimination, continuous model
- MeSH terms
- Aged, Female, Humans, Male, Middle Aged, Respiratory Function Tests, Retrospective Studies, Models, Statistical, Comorbidity, Survival Analysis, Risk Assessment, Internationality, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. https://app.cochat.ai/papers/10.1183/13993003.01587-2018
- The paper
- Torrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C. (2019). The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. European Respiratory Journal. https://doi.org/10.1183/13993003.01587-2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.